Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
57.55
+0.84 (+1.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
Next >
Walmart, Shopify And Some Other Big Stocks Recording Losses On Tuesday
July 27, 2022
U.S. stocks closed lower on Monday, with the Nasdaq Composite dropping more than 200 points. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
July 25, 2022
Gainers
Via
Benzinga
Short Volatility Alert: Legend Biotech Corporation
June 24, 2022
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went up +6.97% to $51.10. The...
Via
Benzinga
Legend Biotech Shares Move Higher After Bullish BMO Pitch
June 17, 2022
Via
Benzinga
Short Volatility Alert: Legend Biotech Corporation
June 17, 2022
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went down -1.38% to $42.96. The...
Via
Benzinga
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer
June 06, 2022
This biotech stock launched in February to work on CAR-T treatments.
Via
Investor's Business Daily
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
May 28, 2022
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...
Via
Talk Markets
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
May 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
April 01, 2022
Via
Benzinga
EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
March 25, 2022
The European Medicines Agency's CHMP
Via
Benzinga
HFCAA News: 128 Chinese Stocks the SEC Could Delist
May 05, 2022
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.
Via
InvestorPlace
Analyst Ratings For Legend Biotech
March 15, 2022
Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 14, 2022
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
March 05, 2022
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in...
Via
Talk Markets
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
March 01, 2022
Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy
March 01, 2022
The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Week In Review: AffaMed Announced US Approval To Start Clinical Trials
February 19, 2022
AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma. On Saturday, AffaMed announced US approval to...
Via
Talk Markets
FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients
February 15, 2022
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Via
Benzinga
18 Stocks Moving in Thursday's Pre-Market Session
December 16, 2021
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...
Via
Benzinga
46 Biggest Movers From Yesterday
December 16, 2021
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...
Via
Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
December 15, 2021
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 15, 2021
Gainers Gemini Therapeutics (NASDAQ:GMTX) shares moved upwards by 32.92% to $3.23 during Wednesday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.